Neuromodulation and Nerve Ablation for Chronic Pain with NeuroOne CEO Dave Rosa — Episode 252

Key Takeaways

• NeuroOne's electrodes enable both nerve ablation and drug delivery
• CEO Dave Rosa has 30 years medical device leadership experience
• Company raised over $200 million to fund R&D and trials
• Neuromodulation market projected to exceed $10 billion by 2028
• Podcast highlights regulatory pathway challenges for brain‑targeted devices

Pulse Analysis

NeuroOne’s approach merges nerve ablation with neuromodulation, using ultra‑thin, flexible electrodes that can be implanted through a small catheter. This hybrid design promises to reduce surgical trauma while delivering precise electrical stimulation and localized pharmacotherapy directly to the brain or peripheral nerves. By targeting the root causes of chronic pain and seizure activity, the technology aims to improve patient outcomes and lower long‑term healthcare costs compared with conventional drug regimens and open‑brain surgeries.

The chronic‑pain market remains a lucrative frontier, with an estimated 50 million Americans affected and spending projected to surpass $100 billion annually. Neuromodulation devices have captured investor interest, and analysts forecast the sector to exceed $10 billion by 2028. NeuroOne’s added capability for drug delivery differentiates it from pure stimulation competitors, potentially expanding its addressable patient pool to include refractory epilepsy and movement disorders. Such versatility could accelerate adoption in hospitals seeking multi‑modal solutions.

Regulatory clearance for brain‑targeted devices is notoriously complex, requiring robust safety data and often a staged approval pathway. Rosa’s background at C.R. Bard, Boston Scientific, and St. Jude equips NeuroOne with seasoned navigation of FDA processes and reimbursement strategies. The $200 million capital raised underscores confidence from venture and strategic investors, positioning the company to fund pivotal trials and scale manufacturing. If clinical endpoints are met, NeuroOne could become a key acquisition target for larger med‑tech firms looking to broaden their neuro‑intervention portfolios.